drugset / Trial / NCT02309320

A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171

NCT02309320 ↗

Phase 1/2 Completed 53 enrolled Ablynx, a Sanofi company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study is to investigate the safety and tolerability of ALX-0171. The secondary objectives are to evaluate the clinical effect of ALX-0171 and to explore the pharmacodynamics (PD) and the systemic pharmacokinetics (PK) of ALX-0171.

Timeline

Start
2014-12
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ALX-0171 Protein / enzyme biologic — Inhaled